Elanco Animal Health (NYSE:ELAN) PT Lowered to $16.00 at Piper Sandler

Elanco Animal Health (NYSE:ELAN) had its target price trimmed by Piper Sandler from $19.00 to $16.00 in a report published on Monday morning, Benzinga reports. They currently have a neutral rating on the stock.

Separately, Barclays dropped their price objective on Elanco Animal Health from $23.00 to $21.00 and set an overweight rating on the stock in a research note on Friday, June 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $17.57.

Elanco Animal Health Trading Up 0.9 %

NYSE ELAN opened at $14.13 on Monday. The business’s 50-day moving average price is $16.48 and its two-hundred day moving average price is $15.70. Elanco Animal Health has a 12 month low of $8.52 and a 12 month high of $18.80. The firm has a market capitalization of $6.98 billion, a PE ratio of -5.33, a price-to-earnings-growth ratio of 1.40 and a beta of 1.42. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.45 EPS. The business’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect that Elanco Animal Health will post 0.93 EPS for the current year.

Insider Transactions at Elanco Animal Health

In related news, Director William F. Doyle acquired 15,000 shares of the stock in a transaction dated Tuesday, May 21st. The stock was purchased at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the purchase, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.57% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp bought a new position in Elanco Animal Health during the fourth quarter valued at $37,000. Global Financial Private Client LLC bought a new position in Elanco Animal Health during the first quarter valued at $72,000. Tower Research Capital LLC TRC grew its holdings in Elanco Animal Health by 169.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock valued at $93,000 after purchasing an additional 3,906 shares during the period. Acadian Asset Management LLC bought a new position in Elanco Animal Health during the third quarter valued at $95,000. Finally, Capstone Investment Advisors LLC bought a new position in Elanco Animal Health during the first quarter valued at $167,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.